These interrelated mechanisms of metabolic dysregulation, insulin resistance, inflammation, and apoptosis drive the initiation and progression of MASLD through a complex network of signaling pathways. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.